Скачать или смотреть The advancements and remaining challenges in precision medicine for CLL

Richard Rosenquist, MD, PhD, Karolinska Institute, Solna, Sweden, speaks about the advancements and remaining challenges in precision medicine for chronic lymphocytic leukemia (CLL). He highlights the transition from chemoimmunotherapy to targeted therapies such as BTK and BCL2 inhibitors, while addressing ongoing challenges in treatment sequencing and patient response. Prof. Rosenquist emphasizes the need for deep molecular profiling alongside new therapies to develop predictive markers for treatment response. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.